Accordingly, in patient-derived colon cancers stratified according to their consensus molecular signature, the same QKI, RBM24, and MBNL2 genes were found to have increased expression in CMS4 tumors, known for their pronounced mesenchymal composition and poor prognosis (Guinney et al., 2015). This evidence concerns the gene MBNL2 and malignant colon neoplasm.